Prenetics Global Limited (NASDAQ:PRE) Given Consensus Recommendation of “Moderate Buy” by Analysts

Prenetics Global Limited (NASDAQ:PRE) has received an average recommendation of “Moderate Buy” from the five research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $34.25.

Several analysts recently commented on the stock. Benchmark raised their price target on shares of Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a research report on Tuesday, April 21st.

Institutional Trading of Prenetics Global

Several hedge funds and other institutional investors have recently modified their holdings of the company. 683 Capital Management LLC bought a new stake in Prenetics Global in the fourth quarter worth approximately $1,181,000. JPMorgan Chase & Co. bought a new position in shares of Prenetics Global in the 3rd quarter valued at approximately $65,000. Kingsview Wealth Management LLC bought a new position in shares of Prenetics Global in the 4th quarter valued at approximately $172,000. Jane Street Group LLC acquired a new stake in Prenetics Global in the 4th quarter worth approximately $1,302,000. Finally, Goldman Sachs Group Inc. acquired a new stake in Prenetics Global in the 4th quarter worth approximately $665,000. 25.01% of the stock is currently owned by hedge funds and other institutional investors.

Prenetics Global Stock Down 3.4%

PRE opened at $18.91 on Friday. The firm has a market capitalization of $319.01 million, a P/E ratio of -4.13 and a beta of 0.26. The stock has a fifty day moving average of $18.66 and a 200-day moving average of $18.47. Prenetics Global has a 12-month low of $7.18 and a 12-month high of $23.63.

Prenetics Global (NASDAQ:PRE) last posted its quarterly earnings results on Wednesday, June 10th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.07). Prenetics Global had a negative net margin of 62.45% and a negative return on equity of 20.33%. The business had revenue of $35.95 million for the quarter, compared to analyst estimates of $36.00 million. On average, analysts expect that Prenetics Global will post -1.4 earnings per share for the current fiscal year.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.